Insider Selling: G1 Therapeutics Inc (GTHX) Insider Sells $150,096.00 in Stock

G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $39.75, for a total value of $150,096.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Rajesh Malik also recently made the following trade(s):

NASDAQ GTHX opened at $41.35 on Monday. The company has a market capitalization of $1.54 billion, a PE ratio of -11.58 and a beta of 1.16. G1 Therapeutics Inc has a 12 month low of $18.03 and a 12 month high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.08. Analysts forecast that G1 Therapeutics Inc will post -2.49 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GTHX. California State Teachers Retirement System boosted its holdings in shares of G1 Therapeutics by 64.6% in the 1st quarter. California State Teachers Retirement System now owns 20,576 shares of the company’s stock valued at $762,000 after buying an additional 8,076 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of G1 Therapeutics in the 1st quarter valued at approximately $659,000. TD Asset Management Inc. boosted its holdings in shares of G1 Therapeutics by 26.4% in the 2nd quarter. TD Asset Management Inc. now owns 32,668 shares of the company’s stock valued at $1,420,000 after buying an additional 6,832 shares during the last quarter. Alps Advisors Inc. boosted its holdings in shares of G1 Therapeutics by 24.4% in the 2nd quarter. Alps Advisors Inc. now owns 47,458 shares of the company’s stock valued at $2,063,000 after buying an additional 9,307 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of G1 Therapeutics in the 2nd quarter valued at approximately $904,000. 64.04% of the stock is owned by institutional investors.

A number of equities analysts have weighed in on GTHX shares. Needham & Company LLC upped their price target on G1 Therapeutics to $76.00 and gave the stock a “buy” rating in a research report on Tuesday, September 18th. BidaskClub downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $79.00 price target on shares of G1 Therapeutics in a research report on Monday, September 17th. BTIG Research began coverage on G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $74.00.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.